NOVO INTEGRATED SCIENCES, INC. Financials Novo Integrated Sciences, Inc.
Equities
NVOS
US67011T3005
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6171 USD | -8.65% |
|
+19.83% | -24.84% |
Valuation
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 207.9 | 98.2 | 93.86 | 48.21 | 51.65 | 21.96 |
| Enterprise Value (EV) 1 | 209.9 | 101.2 | 96.19 | 53.63 | 62.95 | 26.01 |
| P/E ratio | -98.5 x | -243 x | -18.7 x | -10.1 x | -1.48 x | -1.08 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 23.4 x | 10.4 x | 11.9 x | 5.18 x | 4.4 x | 1.75 x |
| EV / Revenue | 23.6 x | 10.7 x | 12.2 x | 5.76 x | 5.36 x | 2.07 x |
| EV / EBITDA | -140 x | -228 x | -34.5 x | -21 x | -9.59 x | -4.16 x |
| EV / FCF | -241 x | -110 x | 78.8 x | 84.9 x | 740 x | 130 x |
| FCF Yield | -0.42% | -0.91% | 1.27% | 1.18% | 0.14% | 0.77% |
| Price to Book | 1,032 x | 3.84 x | 3.17 x | 1.1 x | 2.33 x | 0.89 x |
| Nbr of stocks (in thousands) | 2,079 | 2,237 | 2,347 | 2,649 | 3,102 | 15,684 |
| Reference price 2 | 100.0 | 43.90 | 40.00 | 18.20 | 16.65 | 1.400 |
| Announcement Date | 11/6/18 | 11/20/19 | 12/9/20 | 12/14/21 | 4/3/23 | 12/14/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 8.894 | 9.422 | 7.861 | 9.305 | 11.74 | 12.57 |
| EBITDA 1 | -1.496 | -0.4432 | -2.788 | -2.55 | -6.567 | -6.25 |
| EBIT 1 | -1.569 | -0.5404 | -4.233 | -4.274 | -9.586 | -8.553 |
| Operating Margin | -17.64% | -5.74% | -53.85% | -45.93% | -81.67% | -68.03% |
| Earnings before Tax (EBT) 1 | -2.117 | -0.4036 | -4.924 | -4.471 | -33.07 | -13.27 |
| Net income 1 | -2.108 | -0.392 | -4.915 | -4.462 | -32.85 | -13.21 |
| Net margin | -23.7% | -4.16% | -62.53% | -47.95% | -279.86% | -105.11% |
| EPS 2 | -1.016 | -0.1804 | -2.134 | -1.801 | -11.28 | -1.300 |
| Free Cash Flow 1 | -0.8725 | -0.9185 | 1.221 | 0.6315 | 0.0851 | 0.2003 |
| FCF margin | -9.81% | -9.75% | 15.54% | 6.79% | 0.72% | 1.59% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/6/18 | 11/20/19 | 12/9/20 | 12/14/21 | 4/3/23 | 12/14/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 2.05 | 3.05 | 2.33 | 5.42 | 11.3 | 4.06 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -1.368 x | -6.873 x | -0.8345 x | -2.124 x | -1.72 x | -0.6488 x |
| Free Cash Flow 1 | -0.87 | -0.92 | 1.22 | 0.63 | 0.09 | 0.2 |
| ROE (net income / shareholders' equity) | 103% | -3.14% | -17.9% | -12.2% | -100% | -57% |
| ROA (Net income/ Total Assets) | -19.1% | -1.82% | -7.82% | -5.49% | -11.7% | -14% |
| Assets 1 | 11.02 | 21.48 | 62.86 | 81.3 | 281.9 | 94.47 |
| Book Value Per Share 2 | 0.1000 | 11.40 | 12.60 | 16.50 | 7.150 | 1.570 |
| Cash Flow per Share 2 | 0.3300 | 0.9300 | 0.8800 | 3.120 | 0.7000 | 0.0300 |
| Capex 1 | 0.18 | 0.24 | 0.01 | 0.26 | 0.19 | 0.05 |
| Capex / Sales | 2.01% | 2.54% | 0.15% | 2.75% | 1.62% | 0.39% |
| Announcement Date | 11/6/18 | 11/20/19 | 12/9/20 | 12/14/21 | 4/3/23 | 12/14/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.84% | 11.76M | |
| -14.25% | 85.35B | |
| +14.46% | 81.95B | |
| +9.37% | 28.99B | |
| -11.40% | 16.98B | |
| -0.36% | 16.85B | |
| +0.22% | 15.35B | |
| +4.32% | 12.42B | |
| -2.34% | 11.88B | |
| +32.69% | 12.19B |
- Stock Market
- Equities
- NVOS Stock
- Financials Novo Integrated Sciences, Inc.
